Caribou Biosciences vs Janux Therapeutics
Caribou Biosciences reported revenue of $11 million in fiscal 2025, about the same as Janux Therapeutics' $10 million in fiscal 2025. Caribou Biosciences' revenue grew 11.7% in its latest year, and Janux Therapeutics' fell 5.5%. Caribou Biosciences had an operating margin of -1329.4%, against -1576.7% at Janux Therapeutics. Free cash flow was −$112 million at Caribou Biosciences and −$83 million at Janux Therapeutics.
Side by side
| Caribou Biosciences | Janux Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $11M | $10M |
| Revenue growth | 11.7% | −5.5% |
| Revenue growth a year, last 5 years | −2.0% | — |
| Gross margin | — | — |
| Operating margin | −1,329.4% | −1,576.7% |
| Net margin | −1,327.4% | −1,136.2% |
| Free cash flow | −$112M | −$83M |
| Free cash flow margin | −1,006.8% | −832.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.4% | 15.3% |
| Last close | $0.31 | $10.29 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $33,875 | sold $457,063 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Caribou BiosciencesJanux Therapeutics
Operating margin
Percent of revenue
Caribou BiosciencesJanux Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Caribou BiosciencesJanux Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Caribou Biosciences and Janux Therapeutics pages.